CDFF332A12101
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
- NCT04895748 ↗
- Terminated
- Novartis Pharmaceuticals
- Focused
We haven't built an HCP commentary report on CDFF332A12101 (DFF332; DFF332 plus everolimus; DFF332 plus spartalizumab plus taminadenant in advanced/relapsed ccRCC and malignancies with HIF2α stabilizing mutations) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CDFF332A12101 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2α Stabilizing Mutations
- Phase
- Phase 1
- Status
- Terminated
- Conditions
- Carcinoma, Renal Cell
- Interventions
- DFF332; RAD001; PDR001; NIR178
- Arms
- Arm 1 Dose Escalation DFF332 · Experimental
- Arm 2 Dose Escalation DFF332 + Everolimus · Experimental
- Arm 3 Dose Escalation DFF332 + Spartalizumab + Taminadenant · Experimental
- Arm 1a Dose Expansion DFF332 in ccRCC · Experimental
- Arm 1b Dose Expansion DFF332 in HIF stabilizing malignancies · Experimental
- Arm 2a Dose Expansion DFF332 + Everolimus in ccRCC · Experimental
- Arm 3a Dose Expansion DFF332 + Spartalizumab + Taminadenant in ccRCC · Experimental
- Enrollment
- 40
- Primary outcomes
- Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
- Number of participants with dose interruptions and dose reductions
- Dose intensity for DFF332 for dose escalation and expansion
- Incidence of Dose Limiting Toxicities (DLTs) in Cycle 1 (28 days) for DFF332 as a single agent and in combinations
- Sponsor
- Novartis Pharmaceuticals
- Start
- Nov 30, 2021
- Primary completion
- Feb 13, 2026
- Results posted
- No
- Registry record
- NCT04895748 · updated Mar 3, 2026